- Closing an underwritten public offering of $8.5 million gross proceeds, providing necessary funding to continue preparations for a planned Phase III clinical trial;
- Presenting clinical data on Tovaxin during a poster session at the 63 rd annual American Academy of Neurology (AAN) conference, highlighting important efficacy data in a subpopulation of patients that had previously not been exposed to or taken any drugs for the treatment of their MS; and
- Presenting Opexa’s progress in the ongoing clinical development program for Tovaxin at the 13 th annual BIO CEO & Investor Conference in New York and the 6 th annual Cell Therapy Conference in Beijing.
Opexa Therapeutics Reports First Quarter 2011 Financial Results
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.